A screening program using a fourth-generation HIV test identified 78 unsuspected infections among nearly 28,000 tests.
In 2011, Arizona's principal safety net emergency department (ED) implemented universal opt-out HIV screening using a new (fourth-generation) test that detects both HIV antigen and anti-HIV antibody (Architect HIV Ag/Ab Combo Test; Abbott Laboratories). All positive results were confirmed by Western blot testing. Patients aged 18 to 64 undergoing venipuncture as part of their ED care were informed at triage that they would be tested and were given an informed-consent brochure; at this time they could opt out.
During 2011 to 2014, nearly 28,000 HIV tests were performed on 22,500 patients. The test was positive in 105 cases (0.38%), but 27 (26%) were found to be false-positive results on confirmatory testing. There were 78 confirmed HIV diagno…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals